News &
Events

Updated: June 19, 2026

Solaris Pharma Receives FDA Approval for Acyclovir Ointment USP, 5%

Share

Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration on for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5% in 15 g and 30 g tubes, a generic version of reference listed drug ZOVIRAX (acyclovir) Ointment 5%. For more updates, please feel free to email us businessdevelopment@solaris-pharma.com

About Solaris

Solaris Pharma Corporation, A Privately Held Company Headquartered In Somerset, NJ, Is A Specialty Pharmaceutical Company Developing And Commercializing High Value Drug Products With Limited Generic Competitors. Solaris Is Committed To Development Of Complex Dosage Forms And 505(B)(2) Products That Bring Value To Patients By Providing Access To Quality, Affordable Medicine.

Contact

Shalin Jani
CEO
Info@Solaris-Pharma.com

Source: Solaris Pharma Corporation

Press Release